Speech Disorder disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: SPC005 MIFTS: 47	Speech Disorder Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Speech Disorder

MalaCards integrated aliases for Speech Disorder:

Name: Speech Disorder ¹² ¹⁵

Speech Disorders ⁵⁵ ⁴⁴ ⁷³

Classifications:

MalaCards categories:
Anatomical: Mental diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

Symptoms and signs involving speech and voice

Speech disturbances, not elsewhere classified

External Ids:

Disease Ontology ¹² DOID:92

MeSH ⁴⁴ D013064

NCIt ⁵⁰ C5041

ICD10 ³³ R47

UMLS ⁷³ C0037822

Sources

Summaries for Speech Disorder

Disease Ontology : ¹² A communication disorder that involves difficulty with the act of speech production.

MalaCards based summary : Speech Disorder, also known as speech disorders, is related to epilepsy, focal, with speech disorder and with or without mental retardation and mutism, and has symptoms including cluttering, aprosodia and scanning speech. An important gene associated with Speech Disorder is GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A), and among its related pathways/superpathways are Lysosome and Nicotine addiction. The drugs Memantine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, tongue and cortex, and related phenotypes are behavior/neurological and nervous system

Wikipedia : ⁷⁶ Speech disorders or speech impediments are a type of communication disorder where \'normal\' speech is... more...

Sources

Related Diseases for Speech Disorder

Diseases related to Speech Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 80)

#	Related Disease	Score	Top Affiliating Genes
1	epilepsy, focal, with speech disorder and with or without mental retardation	34.0	GRIN2A GRIN2B LOC105371077
2	mutism	30.9	CNTNAP2 GRN
3	stuttering	30.4	CNTNAP2 FOXP2 GNPTAB GNPTG NAGPA
4	aphasia	28.9	FOXP2 GRIN2A GRN
5	speech and communication disorders	28.5	CNTNAP2 FOXP2 GNPTG GRIN2A GRN NAGPA
6	autism	28.3	CNTNAP2 FOXP1 FOXP2 GRIN2A GRIN2B
7	articulation disorder	27.8	CNTNAP2 FOXP2 GNPTAB GNPTG NAGPA SLC17A5
8	grin2a-related speech disorders and epilepsy	12.1
9	epilepsy-aphasia spectrum	11.2
10	spondyloepiphyseal dysplasia-brachydactyly and distinctive speech	10.9
11	intellectual deficit buenos-aires type	10.8
12	neurodegeneration with brain iron accumulation 1	10.6
13	inclusion-cell disease	10.6	GNPTAB GNPTG
14	mucolipidosis iii alpha/beta	10.6	GNPTAB GNPTG
15	mucolipidosis ii alpha/beta	10.5	GNPTAB GNPTG
16	ocular dominance	10.5	GRIN2A GRIN2B
17	centralopathic epilepsy	10.5
18	spastic paraplegia 20, autosomal recessive	10.5
19	pontine tegmental cap dysplasia	10.5
20	echolalia	10.5
21	fetal alcohol spectrum disorder	10.4	GRIN2A GRIN2B
22	fetal alcohol syndrome	10.4	GRIN2A GRIN2B
23	childhood apraxia of speech	10.4	CNTNAP2 FOXP2
24	d-2-hydroxyglutaric aciduria 1	10.3	GRIN2A GRIN2B
25	valproate embryopathy	10.3	GRIN2A GRIN2B
26	reading disorder	10.3	CNTNAP2 FOXP2
27	benign epilepsy with centrotemporal spikes	10.1	CNTNAP2 FOXP2 GRIN2A
28	focal epilepsy	10.1	CNTNAP2 GRIN2A GRIN2B
29	schizophrenia	10.0
30	autism spectrum disorder	9.9	CNTNAP2 FOXP2 GRIN2B
31	microcephaly	9.8
32	epilepsy	9.8
33	disease of mental health	9.7	GRIN2A GRIN2B GRN
34	specific language impairment	9.6	CNTNAP2 FOXP2
35	amyotrophic lateral sclerosis 1	9.6
36	ankyloglossia	9.6
37	cleft palate, isolated	9.6
38	multiple system atrophy 1	9.6
39	treacher collins syndrome 1	9.6
40	otitis media	9.6
41	velocardiofacial syndrome	9.6
42	friedreich ataxia 1	9.6
43	galactosemia	9.6
44	histidinemia	9.6
45	mental retardation, buenos aires type	9.6
46	cognitive function 1, social	9.6
47	asthma	9.6
48	supranuclear palsy, progressive, 1	9.6
49	frontotemporal lobar degeneration with tdp43 inclusions, grn-related	9.6
50	alacrima, achalasia, and mental retardation syndrome	9.6

Graphical network of the top 20 diseases related to Speech Disorder:

Sources

Symptoms & Phenotypes for Speech Disorder

UMLS symptoms related to Speech Disorder:

cluttering, aprosodia, scanning speech, other and unspecified speech disturbances, dysglossia, rhinolalia, other speech disturbances

MGI Mouse Phenotypes related to Speech Disorder:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	9.56	CNTNAP2 GNPTAB GRIN2A GRIN2B GRN KANSL1
2	nervous system	MP:0003631	9.23	CNTNAP2 GNPTAB GRIN2A GRIN2B GRN KANSL1

Sources

Drugs & Therapeutics for Speech Disorder

Drugs for Speech Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Memantine

Approved, Investigational

Phase 4,Phase 3,Phase 2

19982-08-2

4054

Dopamine

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

51-61-6, 62-31-7

681

Natalizumab

Approved, Investigational

Phase 4

189261-10-7

Citalopram

Approved

Phase 4

59729-33-8

2771

Levodopa

Approved

Phase 4,Phase 2,Phase 3,Not Applicable

59-92-7

6047

Donepezil

Approved

Phase 4

120014-06-4

3152

Corticosterone

Experimental

Phase 4,Phase 1,Early Phase 1

50-22-6

5753

Neurotransmitter Agents

Phase 4,Phase 2,Phase 3,Not Applicable

Nootropic Agents

Phase 4,Phase 2,Phase 1,Not Applicable

Dopamine Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 2,Phase 3,Not Applicable

Excitatory Amino Acid Antagonists

Phase 4,Phase 3,Phase 2

Excitatory Amino Acids

Phase 4,Phase 3,Phase 2

Protective Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antiparkinson Agents

Phase 4,Phase 2,Phase 3,Not Applicable

Autonomic Agents

Phase 4,Phase 2,Phase 3,Not Applicable

Dopamine agonists

Phase 4,Not Applicable

Fluorodeoxyglucose F18

Phase 4,Phase 2,Phase 1

Cholinergic Agents

Phase 4,Phase 2,Not Applicable

Serotonin Agents

Phase 4

Cholinesterase Inhibitors

Phase 4,Phase 2,Not Applicable

Serotonin Uptake Inhibitors

Phase 4

Neurotransmitter Uptake Inhibitors

Phase 4

Antidepressive Agents

Phase 4,Phase 1,Phase 2

Antidepressive Agents, Second-Generation

Phase 4

Anti-Infective Agents

Phase 4,Phase 3,Phase 1,Phase 2

Anti-Inflammatory Agents

Phase 4,Phase 2,Phase 3

Psychotropic Drugs

Phase 4,Phase 2,Phase 3,Phase 1

Radiopharmaceuticals

Phase 4,Phase 2

Antiviral Agents

Phase 4,Phase 3,Phase 1,Phase 2

Serotonin

Investigational, Nutraceutical

Phase 4,Phase 3

50-67-9

5202

Methylene blue

Approved, Investigational

Phase 3

61-73-4

Carbidopa

Approved

Phase 2, Phase 3

28860-95-9

34359 38101

Miglustat

Approved

Phase 3,Phase 1

72599-27-0

51634

Cyclophosphamide

Approved, Investigational

Phase 2, Phase 3

50-18-0, 6055-19-2

2907

Dexamethasone

Approved, Investigational, Vet_approved

Phase 2, Phase 3,Phase 3

50-02-2

5743

Busulfan

Approved, Investigational

Phase 2, Phase 3

55-98-1

2478

Prednisolone

Approved, Vet_approved

Phase 2, Phase 3,Phase 3

50-24-8

5755

Benzocaine

Approved, Investigational

Phase 3

1994-09-7, 94-09-7

2337

Methylprednisolone

Approved, Vet_approved

Phase 2, Phase 3,Phase 3

83-43-2

6741

Tenecteplase

Approved

Phase 3,Phase 2

191588-94-0

Clopidogrel

Approved

Phase 3

120202-66-6, 113665-84-2

60606

Aspirin

Approved, Vet_approved

Phase 3

50-78-2

2244

Asenapine

Approved

Phase 3

85650-56-2, 65576-45-6

3001386

tannic acid

Approved, Nutraceutical

Phase 3

1-Deoxynojirimycin

Experimental

Phase 3

19130-96-2

1374

Ecopipam

Investigational

Phase 2, Phase 3

112108-01-7

Neuroprotective Agents

Phase 3,Phase 2,Phase 1

Prednisolone acetate

Phase 2, Phase 3,Phase 3

Dexamethasone acetate

Phase 2, Phase 3,Phase 3

1177-87-3

Interventional clinical trials:

(show top 50) (show all 335)

#	Name	Status	NCT ID	Phase	Drugs
1	Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial	Unknown status	NCT00196703	Phase 4	memantine
2	Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)	Completed	NCT02142205	Phase 4
3	Memantine and Intensive Speech-Language Therapy in Aphasia	Completed	NCT00640198	Phase 4	memantine;memantine;placebo
4	Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial	Completed	NCT00196690	Phase 4	Donepezil
5	Dopaminergic Enhancement of Learning and Memory in Aphasia	Completed	NCT00102869	Phase 4	levodopa
6	Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia	Completed	NCT00545974	Phase 4	memantine;Placebo pill
7	Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia	Completed	NCT00376051	Phase 4	Citalopram
8	Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech	Recruiting	NCT01818661	Phase 4	AV-1451
9	Imaging of Brain Amyloid Plaques in the Aging Population	Enrolling by invitation	NCT00950430	Phase 4	Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
10	Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)	Withdrawn	NCT00127114	Phase 4	Amantadine;Placebo
11	Effects of MTS-r on Speech Production in Non-fluent Aphasia Post-ischemic Stroke Patients	Unknown status	NCT02241213	Phase 3
12	Improvement of Language Disturbances After Stroke by Intensive Training and Electrical Brain Stimulation	Unknown status	NCT00822068	Phase 2, Phase 3
13	Randomized Clinical Trial of Phonological Interventions	Unknown status	NCT00818428	Phase 2, Phase 3
14	AM-111 in the Treatment of Acute Inner Ear Hearing Loss	Completed	NCT02561091	Phase 3	AM-111 0.4 mg/ml;AM-111 0.8 mg/ml
15	Augmenting Language Therapy for Aphasia: Levodopa	Completed	NCT01429077	Phase 2, Phase 3	levodopa/carbidopa;Placebo comparator
16	A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering	Completed	NCT00830154	Phase 2, Phase 3	pagoclone
17	Application of Miglustat in Patients With Niemann-Pick Type C	Completed	NCT01760564	Phase 3	Miglustat
18	Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)	Completed	NCT01626378	Phase 3	TRx0237;Placebo
19	Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia	Completed	NCT00594737	Phase 3	memantine hydrochloride
20	Stem Cell Transplant for Inborn Errors of Metabolism	Completed	NCT00176904	Phase 2, Phase 3	Busulfan, Cyclophosphamide, Antithymocyte Globulin
21	Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).	Recruiting	NCT02909088	Phase 2, Phase 3	Ecopipam 50mg;Ecopipam 100mg
22	Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma	Recruiting	NCT02111785	Phase 2, Phase 3	Dexamethasone
23	A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion	Recruiting	NCT02398656	Phase 3	Tenecteplase;Antiplatelet treatment
24	Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia	Recruiting	NCT00903266	Phase 3
25	Use of Local Intraoperative Steroid in MIS TLIF	Active, not recruiting	NCT03308084	Phase 3	Methylprednisolone;Dexamethasone
26	Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C	Active, not recruiting	NCT02612129	Phase 2, Phase 3	arimoclomol;Placebo
27	Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease	Active, not recruiting	NCT02534844	Phase 2, Phase 3	VTS-270;Sham Procedure Control
28	A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering	Suspended	NCT01684657	Phase 3	Asenapine
29	Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment	Terminated	NCT02809118	Phase 3	AM-111 0.4 mg/ml;AM-111 0.8 mg/ml
30	Non-invasive Repetitive Paraorbital Alternating Current Stimulation Therapy for Aphasia	Terminated	NCT01277575	Phase 3
31	Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)	Terminated	NCT02245568	Phase 3	TRx0237
32	Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study	Unknown status	NCT02540109	Phase 2
33	Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation (CATS)	Unknown status	NCT01924702	Phase 2
34	Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation	Unknown status	NCT01221779	Phase 2
35	Follow-up of Children After Stuttering Treatment	Unknown status	NCT00709072	Phase 2
36	Spacing Lidcombe Program Clinic Visits	Unknown status	NCT00680303	Phase 2
37	Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation	Unknown status	NCT02149160	Phase 2	FRM-0334;Placebo
38	Effects of Tolcapone on Frontotemporal Dementia	Unknown status	NCT00604591	Phase 2	Tolcapone;Placebo
39	Efficacy of Voice Treatment for Parkinson's Disease	Unknown status	NCT00123084	Phase 2
40	Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients	Completed	NCT01255358	Phase 2	Dexamethasone
41	TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion	Completed	NCT01654445	Phase 2	Tenecteplase
42	Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia	Completed	NCT00824512	Phase 2	EGb 761 120 mg;Placebo
43	Long-Term Assessment of Remyelinating Therapy	Completed	NCT02657915	Phase 2	Placebo;BIIB033 100mg/Kg
44	Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)	Completed	NCT00977665	Phase 2	rasagiline mesylate;placebo
45	Effect of Verb Network Strengthening Treatment (VNeST) on Lexical Retrieval in Aphasia	Completed	NCT01300624	Phase 2
46	Randomised Controlled Treatment Study of Selective Mutism	Completed	NCT01002196	Phase 2
47	Treating Intention In Aphasia: Neuroplastic Substrates	Completed	NCT00567242	Phase 1, Phase 2
48	Safety and Efficacy Study of the Investigational Drug Pagoclone, in the Treatment of Persistent Developmental Stuttering (PDS)	Completed	NCT00239915	Phase 2	Pagoclone
49	EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study	Completed	NCT00216255	Phase 2	Pagoclone;Placebo
50	Brief Behavioral Treatment for Anxiety in Young Children	Completed	NCT02051192	Phase 1, Phase 2

Search NIH Clinical Center for Speech Disorder

Cochrane evidence based reviews: speech disorders

Sources

Genetic Tests for Speech Disorder

Sources

Anatomical Context for Speech Disorder

MalaCards organs/tissues related to Speech Disorder:

⁴¹

Brain, Tongue, Cortex, Testes, Liver, Bone, Eye

Sources

Publications for Speech Disorder

Articles related to Speech Disorder:

(show top 50) (show all 81)

#	Title	Authors	Year
1	Identification of a novel homozygous TRAPPC9 gene mutation causing non-syndromic intellectual disability, speech disorder, and secondary microcephaly. ( 29031008 )	Abbasi A.A....Kaindl A.M.	2017
2	Two unrelated children with overlapping 6q25.3 deletions, motor speech disorders, and language delays. ( 28767196 )	Peter B....Huentelman M.	2017
3	Analysis of a distinct speech disorder seen in chronic manganese toxicity following Ephedrone abuse. ( 27310289 )	Selikhova M....Sanotsky Y.	2016
4	Asthma, hay fever and food allergy are associated with caregiver-reported speech disorders in US children. ( 27091599 )	Strom M.A....Silverberg J.I.	2016
5	Feasibility of Technology Enabled Speech Disorder Screening. ( 27440284 )	Duenser A....Dodd B.	2016
6	Neurophysiologic markers of primary motor cortex for laryngeal muscles and premotor cortex in caudal opercular part of inferior frontal gyrus investigated in motor speech disorder: a navigated transcranial magnetic stimulation (TMS) study. ( 27130564 )	RogiA8 VidakoviA8 M....A9ogaA! Z.	2016
7	Eczema Is Associated with Childhood Speech Disorder: A Retrospective Analysis from the National Survey of Children's Health and the National Health Interview Survey. ( 26520915 )	Strom M.A....Silverberg J.I.	2015
8	Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. ( 25683763 )	Rusz J....RA^A3iA8ka E.	2015
9	Psychogenic speech disorder--a case report. ( 26417806 )	KoA_min-BurzyA8ska A....Krupka-Matuszczyk I.	2015
10	Motor Speech Disorders Associated with Primary Progressive Aphasia. ( 25309017 )	Duffy J.R....Josephs K.A.	2014
11	Detection of chromosomal breakpoints in patients with developmental delay and speech disorders. ( 24603971 )	Utami K.H....Cacheux V.	2014
12	Effectiveness of tongue-tie division for speech disorder in children. ( 25142274 )	Ito Y....Takatama C.	2014
13	Vowel acoustics in dysarthria: speech disorder diagnosis and classification. ( 24687467 )	Lansford K.L....Liss J.M.	2014
14	Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes. ( 25348587 )	Vogel A.P....Poole M.L.	2014
15	Correlation of otologic complaints in soldiers with speech disorders after traumatic brain injury. ( 24275459 )	Dion G.R....Howard N.S.	2014
16	Motor and speech disorders in classic galactosemia. ( 23546812 )	Potter N.L....Shriberg L.D.	2013
17	The interaction between awareness of one' s own speech disorder with linguistics variables: distinctive features and severity of phonological disorder. ( 24408546 )	Dias R.F....Mota H.B.	2013
18	A Variability-Generating Circuit Goes Awry in a Songbird Model of the FOXP2 Speech Disorder. ( 24360538 )	Gadagkar V....Goldberg J.H.	2013
19	Effects of social cognitive impairment on speech disorder in schizophrenia. ( 22416265 )	Docherty N.M....Shakeel M.K.	2013
20	On identifying the processes underlying schizophrenic speech disorder. ( 21562141 )	Docherty N.M.	2012
21	Surgical improvement of speech disorder caused by amyotrophic lateral sclerosis. ( 23171742 )	Saigusa H....Niimi S.	2012
22	Distinguishing groups of children with persistent speech disorder: findings from a prospective population study. ( 22059376 )	Wren Y.E....Miller L.L.	2012
23	Proposal for classifying the severity of speech disorder using a fuzzy model in accordance with the implicational model of feature complexity. ( 22876768 )	Brancalioni A.R....Keske-Soares M.	2012
24	The prevalence of speech disorder in primary school students in Yazd-Iran. ( 21425069 )	Karbasi S.A....Golestan M.	2011
25	The relationship of bottle feeding and other sucking behaviors with speech disorder in Patagonian preschoolers. ( 19845936 )	Barbosa C....Fitzpatrick A.L.	2009
26	Sequential treatment of speech disorders in velocardiofacial syndrome patients: an 8-year retrospective evaluation. ( 19816377 )	Wang G....Salyer K.E.	2009
27	Speech disorder screening test for children. ( 19838570 )	Goulart B.N....Ferreira J.	2009
28	Foreign accent syndrome as a developmental motor speech disorder. ( 19121521 )	MariAn P....De Deyn P.P.	2009
29	[67-year-old patient with speech disorder and dysphagia]. ( 19006046 )	Er F....Erdmann E.	2008
30	An autosomal dominant genetically heterogeneous variant of rolandic epilepsy and speech disorder. ( 18248446 )	Kugler S.L....Pal D.K.	2008
31	Not all ACE inhibitor related angioedema is always evident: a case which is misdiagnosed as panic attack and speech disorder. ( 18047821 )	Gulec M....Karaayvaz M.	2007
32	Teaching phoneme awareness to pre-literate children with speech disorder: a randomized controlled trial. ( 17514541 )	Hesketh A....Nelson V.	2007
33	Speech perception and short-term memory deficits in persistent developmental speech disorder. ( 15896836 )	Kenney M.K....Ludlow C.L.	2006
34	Effects of positive affect on speech disorder in schizophrenia. ( 16319708 )	Cohen A.S....Docherty N.M.	2005
35	Evaluation of speech disorders in children with cleft lip and palate. ( 16044225 )	Paal S....Schuster M.	2005
36	Is slowly progressive anarthria a &quot;pure&quot; motor-speech disorder? Evidence from writing performance. ( 16006336 )	Lucchelli F....Papagno C.	2005
37	Intervention for children with severe speech disorder: a comparison of two approaches. ( 16195201 )	Crosbie S....Dodd B.	2005
38	Educational consequences of developmental speech disorder: Key Stage 1 National Curriculum assessment results in English and mathematics. ( 15130186 )	Nathan L....Snowling M.J.	2004
39	Is the intensity of Schneiderian symptoms related to handedness and speech disorder in subjects with psychosis? ( 14984875 )	Verdoux H....Franck N.	2004
40	A reconsideration of Moses' speech disorder. ( 12706914 )	Marshall C.	2003
41	Speech disorder related to tacrolimus-induced pontine myelinolysis after orthotopic liver transplantation. ( 12819864 )	Ravaioli M....Cavallari A.	2003
42	Postoperative speech disorder after medial frontal surgery: role of the supplementary motor area. ( 12601097 )	Krainik A....Marsault C.	2003
43	The speech disorder of Doc in Walt Disney's &quot;Snow White and the Seven Dwarfs&quot;. ( 11468334 )	Biran I....Steiner I.	2001
44	Speech disorder in schizophrenia: review of the literature and exploration of its relation to the uniquely human capacity for language. ( 11596849 )	Delisi L.E.	2001
45	Speech disorder in children with Down's syndrome. ( 11489052 )	Dodd B....Thompson L.	2001
46	Risk for speech disorder associated with early recurrent otitis media with effusion: two retrospective studies. ( 10668654 )	Shriberg L.D....Block M.G.	2000
47	Is stuttering a speech disorder? ( 10098277 )	Cooper E.B....De Nil L.F.	1999
48	Growth retardation, distinct oriental-like facies, glaucoma, brachydactyly, ventricular septal defect and speech disorder. An unknown entity. ( 10546095 )	Dacou-Voutetakis C....Apostolakis A.	1999
49	[Exclusion of receptive speech disorders with the ADOS (Autism Diagnostic Observation Schedule)]. ( 10637975 )	Noterdaeme M....Amorosa H.	1999
50	Analysis of speech disorders in acute pseudobulbar palsy: a longitudinal study of a patient with lingual paralysis. ( 9926359 )	Leroy-Malherbe V....Arabia C.	1998

Sources

Genes for Speech Disorder

Genes related to Speech Disorder (0 elite genes):

(show all 14)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	GRIN2A	Glutamate Ionotropic Receptor NMDA Type Subunit 2A	Protein Coding	43.87	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Summaries Variants (show sections)
2	FOXP2	Forkhead Box P2	Protein Coding	31.84	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	15056695 12815709 16407075 (more) 20429420
3	GNPTG	N-Acetylglucosamine-1-Phosphate Transferase Subunit Gamma	Protein Coding	24.92	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders (show sections)
4	NAGPA	N-Acetylglucosamine-1-Phosphodiester Alpha-N-Acetylglucosaminidase	Protein Coding	24.75	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders (show sections)
5	GNPTAB	N-Acetylglucosamine-1-Phosphate Transferase Subunits Alpha And Beta	Protein Coding	24.51	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders (show sections)
6	FOXP1	Forkhead Box P1	Protein Coding	24	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	15056695
7	TRAPPC9	Trafficking Protein Particle Complex 9	Protein Coding	20.95	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	GRIN2B	Glutamate Ionotropic Receptor NMDA Type Subunit 2B	Protein Coding	17.02	GeneCards inferred via : Variants (show sections)
9	CNTNAP2	Contactin Associated Protein Like 2	Protein Coding	16.66	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
10	SOCS3	Suppressor Of Cytokine Signaling 3	Protein Coding	16.27	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
11	SLC17A5	Solute Carrier Family 17 Member 5	Protein Coding	15.88	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
12	GRN	Granulin Precursor	Protein Coding	15.78	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
13	KANSL1	KAT8 Regulatory NSL Complex Subunit 1	Protein Coding	15.34	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
14	LOC105371077	Uncharacterized LOC105371077	RNA Gene	7.37	GeneCards inferred via : Variants (show sections)

Sources

Variations for Speech Disorder

Sources

Expression for Speech Disorder

Search GEO for disease gene expression data for Speech Disorder.

Sources

Pathways for Speech Disorder

Pathways related to Speech Disorder according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Lysosome ³⁷	11.01	GNPTAB GNPTG NAGPA SLC17A5
2	Nicotine addiction ³⁷	10.92	GRIN2A GRIN2B
3	nNOS Signaling at Neuronal Synapses ⁶⁴	10.72	GRIN2A GRIN2B
4	Reelin signaling pathway ¹	10.62	GRIN2A GRIN2B
5	SALM protein interactions at the synapses ⁶⁶	10.28	GRIN2A GRIN2B

Sources

GO Terms for Speech Disorder

Cellular components related to Speech Disorder according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	postsynaptic density membrane	GO:0098839	9.16	GRIN2A GRIN2B
2	synaptic membrane	GO:0097060	8.96	GRIN2A GRIN2B
3	NMDA selective glutamate receptor complex	GO:0017146	8.62	GRIN2A GRIN2B

Biological processes related to Speech Disorder according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cerebral cortex development	GO:0021987	9.5	CNTNAP2 FOXP2 TRAPPC9
2	lysosome organization	GO:0007040	9.48	GNPTAB NAGPA
3	carbohydrate phosphorylation	GO:0046835	9.46	GNPTAB GNPTG
4	ionotropic glutamate receptor signaling pathway	GO:0035235	9.43	GRIN2A GRIN2B
5	glutamate receptor signaling pathway	GO:0007215	9.4	GRIN2A GRIN2B
6	excitatory chemical synaptic transmission	GO:0098976	9.37	GRIN2A GRIN2B
7	vocal learning	GO:0042297	9.26	CNTNAP2 FOXP2
8	calcium ion transmembrane import into cytosol	GO:0097553	9.16	GRIN2A GRIN2B
9	secretion of lysosomal enzymes	GO:0033299	8.96	GNPTAB NAGPA
10	N-glycan processing to lysosome	GO:0016256	8.62	GNPTAB GNPTG

Molecular functions related to Speech Disorder according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	androgen receptor binding	GO:0050681	9.37	FOXP1 FOXP2
2	ionotropic glutamate receptor activity	GO:0004970	9.32	GRIN2A GRIN2B
3	extracellularly glutamate-gated ion channel activity	GO:0005234	9.26	GRIN2A GRIN2B
4	NMDA glutamate receptor activity	GO:0004972	9.16	GRIN2A GRIN2B
5	glutamate-gated calcium ion channel activity	GO:0022849	8.96	GRIN2A GRIN2B
6	UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase activity	GO:0003976	8.62	GNPTAB GNPTG

Sources

Sources for Speech Disorder

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia